Population pharmacokinetics and exposure-clinical outcome relationship of remdesivir major metabolite GS‐441524 in patients with moderate and severe COVID‐19

• 主要な著者: Ryo Tamura (著者), Kei Irie (著者), Atsushi Nakagawa (著者), Hirohito Muroi (著者), Masaaki Eto (著者), Hiroaki Ikesue (著者), Nobuyuki Muroi (著者), Shoji Fukushima (著者), Keisuke Tomii (著者), Tohru Hashida (著者)
• フォーマット: 図書
• 出版事項: Wiley, 2023-04-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Abstract Although remdesivir, a prodrug of nucleoside analog (GS‐441524), has demonstrated clinical benefits in coronavirus disease 2019 (COVID‐19) treatment, its pharmacokinetics (PKs) in patients with COVID‐19 remain poorly understood. Therefore, in this study, the PKs of remdesivir and its major...